多西紫杉醇联合奥沙利铂和希罗达治疗晚期胃癌近期疗效观察

目的:观察多西紫杉醇联合奥沙利铂和希罗达治疗晚期胃癌客观疗效和不良反应?方法:多西紫杉醇35 mg/m2,静脉滴注,第1?8天;奥沙利铂130 mg/m2,静脉滴注,第1天;希罗达1 250 mg/(m2·d),分2次口服,连服14天,28天为1个周期?每例患者接受2个周期以上方可评价疗效?结果:32例中有30例可评估疗效,所有患者均可评估不良反应?CR 1例,PR12例,SD 9例,PD 8例,有效率为43.3%(13/30),中位疾病进展时间5.8个月,不良反应主要为骨髓抑制?脱发?结论:多西紫杉醇联合奥沙利铂和希罗达治疗晚期胃癌是可行?安全及有效的?

Clinical effects of docetaxel combined with oxaliplatin and xeloda on treatment of advanced gastric carcinoma

Objective:To evaluate the efficacy and toxicity of docetaxel combined with oxaliplatin and xeloda on treatment of advanced gastric carcinoma. Methods:Thirty-two patients were treated with docetaxel 35 mg/m2 on day 1,8,combined with oxaliplatin 130 mg/m2 on day 1,and xeloda 1 250 mg/(m2·d) twice daily,on day 1~14,with 28 days as a course of treatment. All the patients were treated with more than two courses of chemotherapy. Results:All patients were assessable for toxicity,and 30 of 32 patients were assessable for response. In evaluable 30 patients,CR 1 case,PR 12 cases,SD 9 cases,and PD 8 cases. The response rate was 43.3%(13/30). Median TTP was 5.8 months. The major toxicities were bone suppression and alopecia. Conclusion:Docetaxel combined with oxaliplatin and xeloda are feasible,effective and safe for patients with advanced gastric carcinoma.